Clinical performance of HPV assays for detection of CIN2+
| Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Proportional agreement* (95% CI) | |
|---|---|---|---|---|---|
| HC2 at c/o 1 | 100 (lower bound 85) | 79 (76 to 81) | 10 (6 to 14) | 100 (lower bound 100) | 79 (77 to 82) |
| HC2 at c/o 2 | 96 (78 to 100) | 82 (80 to 84) | 11 (7 to 16) | 100 (99 to 100) | 82 (80 to 85) |
| Cervista | 96 (78 to 100) | 75 (72 to 77) | 8 (5 to 12) | 100 (99 to 100) | 75 (72 to 78) |
| AHPV | 91 (72 to 99) | 84 (81 to 86) | 12 (7 to 17) | 100 (99 to 100) | 84 (81 to 86) |
| rtHPV | 100 (lower bound 85) | 78 (75 to 80) | 9 (6 to 14) | 100 (lower bound 100) | 78 (75 to 81) |
| COBAS | 100 (lower bound 85) | 75 (72 to 78) | 8 (5 to 12) | 100 (lower bound 100) | 75 (73 to 78) |
| Cytology† | 83 (61 to 95) | 95 (94 to 97) | 29 (19 to 42) | 100 (99 to 100) | 95 (94 to 96) |
*Relative to histology (CIN2+).
†At a threshold of mild dyskaryosis or worse.
Detailed clinical information relating to cytology referral categories is available as online supplementary tables.
AHPV, aptima HPV test; CIN, cervical intraepithelial neoplasia; c/o, cut off; HC2, hybrid capture 2 test; HPV, human papillomavirus; NPV, negative predictive value; PPV, positive predictive value; rtHPV, real time HPV test.